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Abstract
Alternatively activated macrophages (M2) have regenerative properties and shown
promise as cell therapy in chronic kidney disease. However, M2 plasticity is one
of the major hurdles to overcome. Our previous studies showed that genetically
modified macrophages stabilized by neutrophil gelatinase‐associated lipocalin
(NGAL) were able to preserve their M2 phenotype. Nowadays, little is known
about M2 macrophage effects in diabetic kidney disease (DKD). The aim of the
study was to investigate the therapeutic effect of both bone marrow‐derived M2
(BM‐фM2) and ф‐NGAL macrophages in the db/db mice. Seventeen‐week‐old mice
with established DKD were divided into five treatment groups with their controls:
D+BM‐фM2; D+ф‐BM; D+ф‐NGAL; D+ф‐RAW; D+SHAM and non‐diabetic (ND)
(db/‐ and C57bl/6J) animals. We infused 1 × 106 macrophages twice, at baseline
and 2 weeks thereafter. BM‐фM2 did not show any therapeutic effect whereas ф‐
NGAL significantly reduced albuminuria and renal fibrosis. The ф‐NGAL therapy
increased the anti‐inflammatory IL‐10 and reduced some pro‐inflammatory cytoki-
nes, reduced the proportion of M1 glomerular macrophages and podocyte loss
and was associated with a significant decrease of renal TGF‐β1. Overall, our study
provides evidence that ф‐NGAL macrophage cell therapy has a therapeutic effect
on DKD probably by modulation of the renal inflammatory response caused by
the diabetic milieu.
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1 | INTRODUCTION
Chronic kidney disease (CKD) has been recognized as a major health
problem worldwide1 and there is still a global rising incidence and
prevalence.2 Diabetic kidney disease (DKD) is the leading cause of
CKD in developed countries.3 Diabetes involves activation of chronic
inflammation and immune response.4 Therefore, the progression of
DKD is associated with increased of pro‐inflammatory cytokines such
as tumour necrosis factor‐α (TNF‐α) and significant inflammatory cell
infiltration of the kidney. Finally, the advanced form of DKD displays
prominent transforming growth factor (TGF‐β) up‐regulation, mesan-
gial expansion and glomerulosclerosis.5 Indeed, TGF‐β1 increases
extracellular matrix accumulation through the stimulation of collagen
IV and fibronectin production,6 resulting in interstitial fibrosis and
glomerular sclerosis.
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Some drug therapies targeting inflammation on DKD have been
explored with variable success.7 On the other hand, the potential
role of endogenous bone marrow‐derived and stem cells in the
repair of kidney damage is still under exhaustive investigation.8
Therefore, interventions such as cell‐based therapy are being broadly
developed aimed to prevent chronic disease progression9 although
very few may induce renal repair.10 Among potential therapeutic
strategies, macrophage cell‐based therapy provides discordant
results.11,12 Macrophages are associated with tissue damage
although they have also a critical role in host defense and tissue
repair.13,14 Alternatively Activated Macrophages (AAM) also called as
M2, have anti‐inflammatory functions and express high levels of
mannose receptor (CD206), arginase and IL‐10.15,16 Lipocalin‐2 (Lcn‐
2), also called Neutrophil Gelatinase‐Associated lipocalin (NGAL), is
able to promote M2 polarization.17,18 M2 may help to overcome
inflammation and through high endocytic clearance capacities medi-
ate wound healing, tissue remodelling and repair.14 Nevertheless,
M2 macrophages are also associated with fibrosis as they can
secrete components of the extracellular matrix and produce growth
factors that activate epithelial cells and fibroblasts, including
TGF‐β.19 M2 macrophages play a controversial role in DKD but stud-
ies are scarce.20 Hence, modulating macrophages to a protective
phenotype to reduce kidney injury in chronic kidney disease still
needs further investigation. Nevertheless, the mechanisms regulating
the distinct functions of macrophages during tissue repair remain lar-
gely unclear.21
We have previously demonstrated that anti‐inflammatory effects
induced by hepatocyte growth factor (HGF) gene therapy enhanced
the presence of bone marrow‐derived M2 (BM‐ΦM2) macrophages
in the glomeruli of diabetic mice and halted DKD progression. There-
fore, in this study we sought to investigate whether infusion of mod-
ulated ex‐vivo BM‐ΦM2 macrophages provide a therapeutic effect
on DKD in obese db/db mice. Our previous results in UUO mice
demonstrated that those BM‐ΦM2 macrophages secrete TGF‐β, did
not diminish inflammation and displayed a phenotypic M1 switch
when they faced a pro‐inflammatory and pro‐fibrotic milieu.22 To
overcome this limitation, we also investigate an alternative macro-
phage therapy transduced with Neutrophil gelatinase‐associated lipo-
calin (NGAL), which is a M2 phenotypically stabilized cell line
overexpressing the anti‐inflammatory cytokine IL‐10 and showing
low TGF‐β secretion.23
2 | MATERIAL AND METHODS
2.1 | Animals
The experiments complied with the current legislation on animal
experiments in the European Union, and the principles of laboratory
animal care were approved by our institution's Ethics Committee for
Animal Research. Ten‐week‐old diabetic female C57BL/Ks/J mice
(db/db) and non‐diabetic (db/‐ and C57bl/6J) female mice were pur-
chased from Janvier (Laval, France). Animals were given free access
to water and a standard laboratory chow diet.
2.2 | Macrophage cell culture
2.2.1 | Φ‐BM and BM‐ΦM2 macrophages
Primary cultures of murine macrophages were obtained from bone
marrow of C57bl/6J mice purified by CD11b+ negative selection
(EasySep, Grenoble, France). Bone marrow‐derived monocytes were
matured in DMEM/F12 + GlutaMAX (Gibco, Waltham, MA, USA)
medium supplemented with 10% FBS, 1% P/S and with 20 ng/mL
macrophage colony stimulating factor (M‐CSF) to become macro-
phages (Φ‐BM) (ProSpec, East Brunswick, NJ, USA). For BM‐ΦM2,
10 ng/mL of IL‐4 and IL‐13 (Invitrogen, Carlsbad,, CA, USA) were
added the last 3 days to become M2 macrophages. No IL‐4 and IL‐
13 cytokines were added in Φ‐BM macrophage culture. Thus, Φ‐BM
was used as a control for BM‐ΦM2 macrophages.
2.2.2 | Φ‐RAW and Φ‐NGAL macrophages
Mice RAW 264.7 macrophages (Φ‐RAW) were cultured in DMEM/
F12 + GlutaMAX medium supplemented with 10% FBS and 1% P/S.
For Φ‐NGAL group, RAW 264.7 macrophages were cultured and
then transduced ex vivo with the adenoviral vector NGAL as previ-
ously described by the group.24 The adenoviral vector carrying
cDNA encoding recombinant NGAL was elaborated, amplified and
purified by ViraQuest, Inc (North Liberty, IA, USA). We previously
reported the control vector Φ‐βGAL as a control vector for the Φ‐
NGAL transduction.22 We analysed Φ‐βGAL macrophages before
infusion and showed no differences compared to Φ‐RAW macro-
phages (Figure S1), but obviously show a difference regarding their
average life expectancy. Tacking this feature into account, we use
NGAL modified cell line for chronic models, such as DKD or Unilat-
eral Ureteral Obstruction (UUO).
2.3 | Experimental design and study groups
Mice were divided into five treatment groups with their respective
controls and followed for four weeks: (a) D+BM‐ΦM2 (n = 9), dia-
betic animals treated with BM‐ΦM2; (b) D+Φ‐BM (n = 9), diabetic
animals treated with Φ‐BM as control for BM‐ΦM2; (c) D+Φ‐NGAL
(n = 9), diabetic animals treated with Φ‐NGAL; (d) D+Φ‐RAW (n = 9),
diabetic animals treated with Φ‐RAW as control for Φ‐NGAL; (e)
D+SHAM (n = 9), diabetic animals treated with saline Buffer as age‐
matched control group and (f) db/‐ and C57bl/6J mice as non‐diabetic
(ND) (n = 8) animals. For cell therapy, one million (1 × 106) of Φ‐BM,
BM‐ΦM2, Φ‐RAW or Φ‐NGAL macrophages were infused on 17‐
week‐old and 19‐week‐old db/db mice, respectively, by intravenous
injection in the tail vein. Mice were killed under anaesthesia and
evaluated on 21‐week‐old.
2.4 | Monitoring
Animals were followed from 10 to 21 weeks of age. During this per-
iod glucose levels and body weight were measured weekly. Glucose
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was measured using the ACCU‐CHEK Performa blood glucose meter
(Roche, Basel, Switzerland). Blood was obtained from the tail vein
and samples were collected in order to analyse the serum creatinine
at three time points: before cell therapies (15 weeks), when cell ther-
apies were performed (20 weeks) and before mice were killed
(21 weeks). Mice were placed in metabolic cages in order to collect
24 hours urine specimens before cell therapies (15 weeks), during
cell therapies (18 weeks, 19 weeks and 20 weeks, respectively) and
after macrophage cell therapies (21 weeks). Urine samples were col-
lected in order to analyse the urinary albumin concentration. Urine
creatinine and serum creatinine were determined following Jaffe's
and GLDH reactions (Olympus Autoanalyzer AU400, Hamburg, Ger-
many) in the Veterinary Clinical Biochemistry Laboratory of Universi-
tat Autònoma de Barcelona. Urine albumin excretion was
determined using a specific commercially available ELISA kit (Albu-
mine Blue, la Hulpe, Belgium).
2.5 | Detection of the infused macrophages in the
kidney of db/db mice
In order to assess whether adaptive transfer of exogenous ф‐NGAL
macrophages reached diabetic kidneys, macrophages were cultured
and then stained with a red fluorescent membrane label Vivo-
track680 (Vertex, Barcelona, Spain) according to manufacturer's
instruction. One million (1 × 106) of labelled macrophages were
injected into mice by a single tail‐vein injection. Mice were killed
24 hours after macrophage injection and were assayed and quanti-
fied. Data were acquired and analyzed using FACS Diva software.
2.6 | Optical microscopy, immunohistochemical,
immunofluorescence and confocal studies
For conventional histology, 3 μm thick renal sections were fixed in
10% (vol./vol.) formalin and embedded in paraffin. Renal slices were
stained with fibronectin and Masson's trichrome for optical micro-
scopy assessment. Fibronectin (1:500) (Abcam, Madrid, Spain) and
Anti‐collagen IV (1:100; Millipore, Livingston, UK) were stained using
the immunohistochemical technique described previously.25 Slides
were analysed by optical microscopy to assess fibrosis and glomeru-
losclerosis and quantified using ImageJ software in each non‐overlap-
ping cortical field from the cortical region. For histological analysis
21‐35 glomeruli per animal were evaluated. A magnification of ×400
was assessed to quantify histological sections (7 per animal). Values
are obtained as relative stained area (%).
Confocal studies (Leica TCS‐SL, Mannheim, Germany) were per-
formed on paraffin‐embedded renal tissue. Double immunolabelling
of antimouse F4/80 (1:50, LabClinics, Barcelona, Spain) and anti‐
CD86 (1:50, Abcam) were analysed using immunofluorescence.
Slides were stained with F4/80 for macrophages and CD86 for the
M1 subpopulation. Macrophages and M1 subpopulation were evalu-
ated in ten glomeruli per slide and per animal in a blinded manner
(n = 9 each group). The percentage of M1+ with respect to F4/80+
macrophages was calculated. Alexa Fluor 488 (green) and Alexa
Fluor555 (red) were used as secondary antibodies (Invitrogen). For
podocyte assessment, nuclear marker WT‐1 (1:30 Santa Cruz
Biotechnology, Heidelberg, Germany) and Alexa Fluor 488 as a sec-
ondary antibody (green) (1:1000, Invitrogen) were used. In a blinded
manner, podocytes were quantified in ten glomeruli per sample and
calculated as podocyte/total nuclei ratio. Nuclei were stained blue
with DRAQ5.
2.7 | Quantitative real‐time PCR
RNA was extracted from kidney as previously described.25 A total
amount of 400 ng RNA was used to perform the reverse transcrip-
tion using a High‐Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Warrington, UK). TGF‐β1, Megalin, IL‐10, TNF‐α, Man-
nose receptor, IL‐1β and CD40 were quantified by TaqMan real‐time
PCR (ABI, Prism 7700, Applied Biosystems) using the comparative
2−[delta][delta]Ct method.
2.8 | Cytokine analysis
Serum cytokines were quantitatively measured by FACS Canto with
the mouse inflammation kit cytometric bead array (CBA) from BD
Bioscience (San Jose, CA, USA). Data were acquired and analysed
using BD CBA software.
2.9 | ELISA
Frozen kidney samples were dissolved and homogenized into a
specific buffer and centrifuged at 3000 g for 15 minutes at 4°C. The
protein concentration was analysed with a Bradford Assay kit
(Thermo Scientific, Rockford, IL, USA). Quantitative assessment of
TNF‐ α (DY410) and TGF‐β1 (DY1679) proteins were carried out by
enzyme‐linked immunosorbent assay (ELISA) (Duo Set ELISA, R&D,
Minneapolis, MN, USA).
2.10 | Statistical analysis
All data are presented as mean ± SE. Group means were com-
pared with either the Student's t‐test or ANOVA for parametric
values, or the Mann–Whitney U test or Krustal‐Wallis test for
non‐parametric values. P ≤ 0.05 was considered to be statistically
significant. All statistical analyses were carried out using StatView
software.
3 | RESULTS
3.1 | BM‐ΦM2 cell therapy does not have
therapeutic effect on DKD
All experimental diabetic groups (D) showed significantly higher body
weight, higher albuminuria and diuresis than the non‐diabetic group
(ND) (Table 1, Figure 1). There were no significant differences between
D+BM‐ΦM2 and D+SHAM mice regarding albuminuria (Table 1 and
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Figure 1), glomerulosclerosis (Figure 2A‐D), renal mRNA gene expres-
sion (Figures 2E and 3C, D), glomerular pro‐inflammatory macrophage
phenotype (Figure 4) and loss of podocytes (Figure 5A, B).
3.2 | Φ‐NGAL macrophage cell therapy displays a
therapeutic effect on DKD
Treatment with Φ‐NGAL macrophages resulted in significant reduc-
tion in urinary albumin from the 19‐week compared to the diabetic
control mice (D+SHAM) (Table 1, Figure 1). Furthermore, the proper
Φ‐NGAL control group, the D+Φ‐RAW group, did not show any
therapeutic effect on DKD. Moreover, those diabetic animals receiv-
ing Φ‐NGAL treatment were the only group displaying a significant
reduction in glomerulosclerosis as well as collagen IV and fibronectin
glomerular deposition compared to D+SHAM and its control group
D+Φ‐RAW mice (Figure 2A‐D).
Infused macrophages reached diabetic kidneys as shown in Fig-
ure S2. Representative plots display that 7.6% of kidney cells were
detected as Vivotrack positive cells. Φ‐NGAL macrophages were
stable M2‐like in terms of anti‐inflammatory and pro‐reparative pro-
file. We measured IL‐10, Mannose Receptor (MR), TNF‐α and IL‐1β
production in transduced macrophages (Figure S3). Results showed
an up‐regulation of anti‐inflammatory mediators in Φ‐NGAL, even
when stimulated with the pro‐inflammatory mediator LPS.
3.3 | Φ‐NGAL macrophage cell therapy reduces
kidney TGF‐β1 overexpression in DKD
As showed in Figure 2E and in agreement with histological data, Φ‐
NGAL treated mice showed a reduction in the TGF‐β1 mRNA
expression in kidney tissue. Kidney TGF‐β1 mRNA was significantly
increased in diabetic mice (D+SHAM) compared to ND. Kidney
TGF‐β1 mRNA remained high in the D+Φ‐BM, D+BM‐ΦM2 and
D+Φ‐RAW groups (Figure 2E). Moreover, kidney TGF‐β1 protein
expression was measured by ELISA and was also significantly
reduced in the D+Φ‐NGAL group (Figure 2F).
3.4 | Φ‐NGAL cell therapy reduces inflammation in
DKD
We first measured serum levels of some pro‐inflammatory cytokines
in all groups in order to test whether macrophage infusion could
modulate inflammation in DKD. The D+SHAM, D+Φ‐RAW and
D+Φ‐BM groups showed higher TNF‐α levels than ND group (Fig-
ure 3A). On the contrary, TNF‐α levels were significantly lower in
D+Φ‐NGAL treated animals compared with diabetic non‐treated
D+SHAM and their control D+Φ‐RAW (Figure 3A). Of note, no
major differences were observed between the D+BM‐ΦM2 group
and its control, the D+Φ‐BM group. We also evaluated the kidney
tissue TNF‐α protein levels by ELISA (Figure 3B). Only the D+Φ‐
NGAL group showed a reduction in TNF‐α kidney protein. Its control
group, D+Φ‐RAW, showed similar TNF‐α than D+SHAM controls.
Although serum TNF‐α was similar in the D+BM‐ΦM2 and
D+SHAM groups, kidney TNF‐α protein expression, assessed by
ELISA, was significantly higher in the D+BM‐ΦM2 than in the
D+SHAM and showed statistical significance compared to its control
group D+Φ‐BM (Figure 3B).
The kidney mRNA CD40 gene expression was up‐regulated in
diabetic animals and it was marginally reduced after D+Φ‐NGAL cell
therapy (Figure 3C). Interestingly, the anti‐inflammatory IL‐10 kidney
gene expression was significantly increased in the D+Φ‐NGAL group
compared with both diabetic control (D+SHAM) and non‐diabetic
groups (ND) (Figure 3D).
3.5 | Φ‐NGAL macrophage cell therapy reduces the
glomerular M1 macrophage ratio
We evaluated the expression of M1 phenotype in glomerular macro-
phages by confocal microscopy. Macrophages were mainly localized
around the glomeruli (Figure 4A). As shown in Figure 4B, diabetic
control mice (D+SHAM) displayed a high ratio of CD86+/F4/80+
macrophages, achieving almost 100%. Φ‐NGAL macrophage infusion
was associated with increased number of glomerular macrophages,
TABLE 1 Baseline and after treatment variables associated with diabetic kidney disease
Characteristic Non‐diabetic D+SHAM D+ф‐RAW D+ф‐NGAL D+ф‐BM D+BM‐ф‐M2
Week 16 (pre‐treatment)
Body weight (g) 17.93 ± 1.2 43.05 ± 2.7a 42.32 ± 5.5a 45.13 ± 3.6a 39.56 ± 2.5a 42.73 ± 3.8a
Glycaemia (mg/dL) 143.5 ± 18.1 552.1 ± 54.7a 583.6 ± 54.7a 534.4 ± 40.1a 599 ± 20.4a 590.75 ± 17.1a
Albuminuria (μg/24 h) 17.24 ± 1.3 420.53 ± 3.6a 422.97 ± 164.4a 403.4 ± 150a 413.7 ± 106.2a 441.1 ± 115.3a
Diuresis (mL) 0.25 ± 0.1 9.2 ± 3.3a 12.3 ± 3a 9.9 ± 1.1a 8.4 ± 3.2a 11.6 ± 4a
Week 20 (post‐treatment)
Body weight (g) 22.83 ± 1.3 40.77 ± 2.5a 38.71 ± 5.7a 40.56 ± 4.5a 34.35 ± 1.7a 41.04 ± 5.1a
Glycaemia (mg/dL) 131.4 ± 14.1 572.7 ± 43.4a 569 ± 35.8a 583.2 ± 20.9a 563.2 ± 53.4a 550.22 ± 59.9a
Albuminuria (μg/24 h) 39.19 ± 17.5 881.1 ± 140a 783.91 ± 210.1a 621.97 ± 90.4a,b 1067.7 ± 357.1a 893.57 ± 187.3a
Diuresis (mL) 1.15 ± 0.3 21.7 ± 4.2a 24.6 ± 7.1a 22.9 ± 4.2a 19.3 ± 1.15a 21.2 ± 4.2a
Diabetic mice (D) showed a significant increase of body weight, glycaemia, albuminuria and diuresis compared to non‐diabetic (ND), both pre and
post‐treatment. After treatment, D+ф‐NGAL displayed a reduction of the albumin excretion. Data are represented in mean ± SE.
aP ≤ 0.05 vs ND; bP ≤ 0.05 vs D+SHAM.
844 | GUITERAS ET AL.
although the proportion of CD86+ (M1) decreased to 74%. On the
other hand, D+BM‐ΦM2 treated mice showed similar proportion of
CD86+/F4/80 glomerular macrophages to diabetic control mice
(D+SHAM).
3.6 | Φ‐NGAL macrophage cell therapy abrogates
podocyte loss and preserves kidney integrity in DKD
We analysed whether macrophage infusion modified the characteris-
tic podocyte loss that appears in DKD. Thus, diabetic control mice
(D+SHAM) displayed a reduced number of podocytes compared to
the non‐diabetic (ND) mice (Figure 5A, B). Remarkably, D+SHAM
treated group showed a decreased podocyte number compared to
D+Φ‐NGAL group. In fact, podocyte number in the Φ‐NGAL group
was similar to that in ND group. Φ‐BM and BM‐ΦM2 treated mice
showed no differences compared to D+SHAM. Moreover, megalin
mRNA gene expression in kidney tissue examination revealed that
epithelial integrity was only preserved in D+Φ‐NGAL‐treated mice
(Figure 5C).
3.7 | Φ‐βGAL vector transduction did not show
alternative M2 phenotype
Transduction of Φ‐βGAL macrophages showed slight mRNA expres-
sion of IL‐10, TNF‐α, NGAL and CD206 molecules compared to
BM‐ΦM2 and Φ‐NGAL macrophages (Figure 6A). Furthermore,
Φ‐βGAL displayed no expression of the alternative M2 phenotype
(CD206) (Figure 6B), contrary to BM‐ΦM2 and Φ‐NGAL macro-
phages that yielded ≥97% of CD206 positive marker, which
demonstrated their alternative M2 phenotype analysed by FACS
cytometer (Figure 6B).
4 | DISCUSSION
In this study, we demonstrated firstly that BM‐ΦM2 macrophage cell
therapy did not exert any therapeutic effect on DKD and secondly
that Φ‐NGAL macrophage cell therapy was associated with a thera-
peutic effect on DKD. The lack of therapeutic effect of the
BM‐ΦM2 macrophage cell therapy is consistent with our previous
findings in the CKD UUO model that demonstrates M2 switching to
M1 in a pro‐inflammatory and pro‐fibrotic environment.22
Hyperglycaemia and the dysregulated metabolic milieu play a
key role in DKD.26 However, in TD2M tight glucose control was
not associated with improved renal and non‐renal outcome.27-29
Thus, although hyperglycaemia plays a major role in DKD initiation
additional effector mechanisms should be involved in the progres-
sion of DKD. Among such mechanisms, inflammation is considered
as a relevant pathogenic factor in the progression of DKD.30
Therefore, the reduction in inflammation has been associated with
a significant reduction in the extracellular matrix accumulation in
DKD.31
NGAL has been described as a marker and potential positive
modulator of inflammation.32 NGAL display anti‐inflammatory prop-
erties in different diseases providing protective effects. One of the
main acting pathways is by interfering the transcription of NF‐kB
dependent genes such as TNF‐alpha and IL‐6.33 Recently, it has
been described NGAL interaction in inflammation by controlling
F IGURE 1 Albumin evolution analysis. Urinary albumin and creatinine were assessed before (15 wk) and during (18 wk, 19 wk, 20 wk and
21 wk) macrophage cell therapies. Non‐diabetic (ND) mice did not show an increase of the albumin/creatinine ratio. Control diabetic mice
(D+SHAM) displayed persistent albumin/creatinine ratio whereas D+Φ‐NGAL treated mice showed a significant reduction from 19 wk. D+Φ‐
RAW as a control to D+Φ‐NGAL and D+Φ‐BM as a control to D+BM‐ΦM2 did not show a significant decrease in any time‐point. Any other
group exhibited a significant decrease. All diabetic mice (D) showed statistical significance vs ND animals. Data are represented as mean ± SE.
*P ≤ 0.05 vs D+SHAM; aP ≤ 0.05 vs ND; bP ≤ 0.05 vs D+Φ‐RAW; cP ≤ 0.05 vs D+Φ‐BM
GUITERAS ET AL. | 845
F IGURE 2 Effect of different macrophage therapies on glomerulosclerosis and fibronectin expression in kidney. Representative histological
images of (A) Masson's trichrome and (B) fibronectin analysis in non‐diabetic (ND) and diabetic (D) treated groups. Control diabetic mice
(D+SHAM) showed increased glomerulosclerosis and fibronectin, which was improved by Φ‐NGAL macrophage infusion as demonstrated by
quantification in ImageJ software (C, D). (E) mRNA gene expression of kidney tissue revealed a significant decrease of TGF‐β1 in diabetic D+Φ‐
NGAL treated mice for its control D+Φ‐RAW and for the diabetic control D+SHAM. (F) Renal tissue homogenates from treated and non‐
treated mice were prepared for enzyme‐linked immunosorbent assay (ELISA) to determine protein levels of TGF‐β1 displaying a significant
decrease only in D+Φ‐NGAL mice compared to diabetic control D+SHAM. Data are represented as mean ± SE. *P ≤ 0.05 vs D+SHAM;
aP ≤ 0.05 vs ND; bP ≤ 0.05 vs D+Φ‐RAW; cP ≤ 0.05 vs D+Φ‐BM
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F IGURE 3 Φ‐NGAL macrophage
therapy reduces inflammation. A, Serum
levels of the pro‐inflammatory TNF‐α
cytokine was assessed and showed a
significant decreased expression in D+Φ‐
NGAL treated mice compared with
D+SHAM and its control group D+Φ‐
RAW. B, Quantification of TNF‐α protein
levels from kidney tissue measured by
ELISA almost reached statistical
significance in D+Φ‐NGAL treated mice. Its
control group D+Φ‐RAW showed the
same expression as diabetic control mice
(D+SHAM). C, CD40 mRNA expression
levels demonstrated a decrease of this
molecule although it did not reach
statistical significance. D, The anti‐
inflammatory cytokine IL‐10 displayed a
significant increase in D+Φ‐NGAL group
compared both with non‐diabetic (ND),
D+SHAM and D+Φ‐RAW. Data are
represented as mean ± SE. *P ≤ 0.05 vs
D+SHAM; aP ≤ 0.05 vs ND; bP ≤ 0.05 vs
D+Φ‐RAW; cP ≤ 0.05 vs D+Φ‐BM
F IGURE 4 Evaluation of glomerular
macrophages expressing CD86 (M1)
marker. Glomerular detail (×400) using F4/
80 (red) and CD86 (green) staining in order
to identify general macrophages and M1
phenotype subpopulation (A). Double
positive macrophages become yellow. The
arrows show F4/80 positive macrophages
that do not co‐express CD86 marker. (B)
Number of macrophages per glomeruli.
Each bar represents the mean number of
macrophages F4/80 per glomeruli and per
group. The black area in the bars indicates
the percentage of the total macrophages
that show M1 phenotype (n = 9 per
group). Data are represented as mean ± SE
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autophagy34 and inflammasome.35 Moreover, in the kidney, NGAL
can indirectly reduce inflammation by blocking necrosis and by mod-
ulating apoptosis and more specifically by activating DAMP HMGB‐
1, as demonstrate in the nephrotoxic serum nephritis.36 Hence,
NGAL may also be one of the key potential modulators of macro-
phage phenotype stabilization and inflammation37,38; thus, promoting
renal epithelial cell integrity and renal recovery after injury.24 Our
group has recently described39 that, in renal epithelial cells, Lcn‐2
acts via binding to its specific receptor and triggers downstream
pathways of proliferation (activation of the PI3K/Akt‐pathway) and
inhibition of PPARγ. Previous data from our group suggested that
the infusion of Φ‐NGAL macrophages, as a result of their IL‐10
overexpression, was effective during the inflammatory phase of renal
ischaemia and reperfusion injury.40 We have also recently reported
that Φ‐NGAL macrophages have reduced cell plasticity and therefore
preserve their anti‐inflammatory and anti‐fibrotic phenotype even
when placed in a pro‐inflammatory and pro‐fibrotic environment.22
Taking into account this rationale we investigated whether Φ‐
NGAL macrophage cell therapy could overcome the limitations of
BM‐ΦM2 and halt the progression of DKD as infused Φ‐NGAL
macrophages reach the diabetic kidney. TNF‐α is probably one of
most relevant inflammatory cytokines involved in DKD. Several stud-
ies suggest that inhibition or altering TNF‐α may exert therapeutic
effect on DKD41,42 even in humans.43 In our study Φ‐NGAL
F IGURE 5 Evaluation of glomerular podocytes. Podocytes are stained with WT‐1 (green) and nuclei with DRAQ5 (blue) (×400). B,
Quantification number of podocytes per nuclei in ten glomeruli; ф‐NGAL therapy increased the presence of glomerular podocytes while its
control group ф‐RAW and the others showed similar results. C, Megalin mRNA expression in kidney tissue demonstrated more renal integrity
in D+ф‐NGAL mice. Each bar represents the mean ± SE from each group. n = 9 in each group diabetic group and n = 8 in ND group.
*P ≤ 0.05 vs D+SHAM; aP ≤ 0.05 vs ND; bP ≤ 0.05 vs D+Φ‐RAW; cP ≤ 0.05 vs D+Φ‐BM
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macrophage cell therapy increased the anti‐inflammatory molecule
IL‐10 and decreased the pro‐inflammatory molecule TNF‐α, suggest-
ing that Φ‐NGAL macrophages could reduce inflammation in DKD.
The anti‐inflammatory effect may have both a direct therapeutic
effect on DKD and at the same time could contribute to M2 pheno-
type stabilization. The lower proportion of glomerular pro‐inflamma-
tory M1 macrophages observed in the Φ‐NGAL group is in
agreement with M2 phenotype stabilization. In fact, we have previ-
ously reported that the reduction in pro‐inflammatory cytokines
increased the proportion of reparative and anti‐inflammatory M2
macrophages in diabetic glomeruli.25
In a seminal investigation published more than 20 years ago,
Pagtalunan et al44 recognized podocyte loss as a relevant contributor
to the progression of DKD. It has been described that podocyte
number correlates with proteinuria and it is one of the best predic-
tors of DKD.45 In addition to other pathogenic mechanisms as
hyperglycaemia‐induced ROS generation,26 inflammation46 can con-
tribute to podocyte loss by causing podocyte apoptosis and detach-
ment. As podocytes are terminally differentiated cells that cannot be
replaced, the remaining podocytes enlarge by cell hypertrophy and
finally dedifferentiate to cell type that contribute to extracellular
matrix accumulation. In our study, we found that only infusion of Φ‐
NGAL macrophages exerted a protective effect on podocyte loss
and was associated with a significant reduction in albuminuria. As
this cell therapy was also the only one that could modulate the
inflammatory response in DKD, it has been suggested that Φ‐NGAL
macrophage cell therapy preserve podocyte number by means of
reducing inflammation. Therefore, our results are in‐line with other
studies suggesting that the reduction in podocyte damage may, in
fact, reduce albuminuria and diabetes progression.47 Albuminuria is a
biomarker of DKD and its severity is considered one of the most
important predictors of DKD progression.48 As previously pointed
out, the reduction in albuminuria in the Φ‐NGAL group may merely
by a reflection of podocyte preservation. Nevertheless, albuminuria
in pathological states such as DKD, can be also because attenuated
tubular reabsorption of albumin.49 Megalin is a large glycoprotein
that is highly expressed in proximal tubular epithelial cells.50 As we
found that Φ‐NGAL macrophage cell therapy was associated with
preserved megalin gene expression and consequently with tubular
epithelial integrity, it is feasible that albumin tubular reabsorption
could also play a role to reduce albuminuria in diabetic animals trea-
ted with Φ‐NGAL.
The fibrogenic cytokine transforming growth factor β (TGF‐β) is
an important transcriptional regulator of cell transdifferentition pro-
moting epithelial to mesenchymal transition and extracellular matrix
accumulation. There is consistent data showing that renal TGF‐β
expression increases in DKD6,51 as it is induced by renin angioten-
sin system activation, metabolic dysregulation and hyperglycaemia.
TGF‐β is considered as one of the most relevant pro‐fibrotic factors
accounting for glomerulosclerosis and interstitial fibrosis in DKD as
well as other chronic nephropathies.52,53 The administration of anti‐
TGF‐β antibodies, antisense TGF‐β1 oligodeoxynucleotides or
knocking off the downstream Smad3 gene prevent and/or reverse
the hypertrophic and pro‐fibrotic effects of hyperglycaemia in
DKD.54
Considering the potential benefit of M2 macrophage cell ther-
apy on DKD it is important to note that M2 macrophages have
anti‐inflammatory properties but are also associated with fibrosis
as they can secrete TGF‐β.19,20 Therefore, in our study we found
that in mice treated either with BM‐ΦM2, Φ‐BM and Φ‐RAW
infusion, the renal TGFβ‐1 as well as renal fibrosis were similar to
that observed in diabetic non‐treated animals. In order to
F IGURE 6 Macrophage gene
expression profile and phenotype
assessment before infusion. A,
Macrophages were cultured and mRNA
expression of IL‐10, TNF‐α, TGFβ‐1, NGAL
and CD206 were measured by qPCR in
fresh cultured BM‐фM2, ф‐β‐GAL and ф‐
NGAL previously to infusion. B, Phenotype
analysis was likewise analysed by FACS
CANTO cytometry and BM‐фM2 and ф‐
NGAL showed high expression of CD206
compared to ф‐β‐GAL. n = 3 in each group.
aP ≤ 0.05 BM‐фM2 vs ф‐NGAL; bP ≤ 0.05
ф‐NGAL vs ф‐β‐GAL
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overcome this limitation, we treated the diabetic mice with a phe-
notypically stabilized M2 cell line expressing low TGF‐β by trans-
ducing NGAL. Interestingly, the Φ‐NGAL macrophage cell therapy
effectively reduced the elevated renal TGF‐β1 as well as the fibro-
tic renal lesions that are the hallmark of DKD. This effect was
dependent on NGAL transduction because the Φ‐RAW group
showed similar renal TGFβ‐1 and fibrosis than the diabetic control
group. The lack of therapeutic effect of BM‐ΦM2 may be because
of M1 switching, TGF‐β1 secretion or both. Actually, in a previous
study we demonstrated that both BM‐ΦM2 and Φ‐NGAL infused
macrophages reach the damaged kidney although the BM‐ΦM2
switch significantly their phenotype to the inflammatory one
M1.22 Also, Zheng et al55 in diabetic animals proved that macro-
phages from the cell therapy were located in spleen immediately
after infusion, and then accumulated progressively both in kidney
and pancreas.
The immunogenicity of those Φ‐RAW macrophages could be
interpreted as a potential limitation in our study. Φ‐RAW macro-
phages derive from monocytic leukaemic cell of BALB/c that carries
H‐2d, and C57Bl/6j carries H‐2b. Therefore, adoptive transfer of cells
to mice with different H‐2 antigen is possibly immunogenic. How-
ever, previous studies from our group and others,22,23,56,57 suggested
that infusing these cells in C57Bl/6j was not immunogenic. Consis-
tent with these results, we did not detect any effect associated with
the potential activation of an effector alloimmune response against
the infused cells in our diabetic mice model.
In summary, our study demonstrates that Φ‐NGAL macrophage
cell therapy has a therapeutic effect on DKD in diabetic mice proba-
bly by modulation of the renal inflammatory response caused by the
diabetic milieu. Our study provides evidence about the limitations of
macrophage cell therapy in kidney diseases and shows a potential
strategy to overcome the inherent M2 plasticity and TGF‐β1 overex-
pression by Φ‐NGAL transduction. Thus, our study paves the way to
new opportunities in DKD treatment.
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